CD8A and cancer: Traditional cancer immunotherapy approaches have focused on isolating MHC-I-restricted TCRs [9,67] or attempting to raise CD8+ mediated responses with cancer vaccines containing MHC-I-restricted epitopes, although several approaches selecting TCRs restricted to MHC-II neo-antigens have now been pursued [59].